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Abstract
Background: Apathy in DM1 has long been acknowledged in clinical practice. However, a major drawback is that
the concept has been only sparsely explored in previous specific studies. This study aimed to determine the prevalence
of apathy in myotonic dystrophy (DM1), to compare it with facioscapulohumeral dystrophy (FSHD) patients and normal
healthy controls, and explore its relationship to psychopathological features and cognitive function.
Methods: Levels of apathy in 38 DM1 patients with adult phenotypes were compared with 19 patients with FSHD and
20 matched controls. Patient participants were consecutively recruited, regarding their interdisciplinary annual evaluation
at the neuromuscular pathology reference center (Institute of Myology, Paris, France), within an 18-month period.
Additional measurements included motor disability, fatigue, depression, anxiety, and cognitive abilities. Inter-group
comparisons were performed using non-parametric Kruskal-Wallis tests and Mann–Whitney U Tests. Intra-group
comparisons were carried out with the Wilcoxon Signed rank and Friedman tests. Also, Spearman’s correlations were
used to assess the strength of linear relationships between pairs of variables. The significance level was set at 0.05.
Results: Global score of apathy was significantly higher in DM1 patients than in FSHD patients (p < 0.01) and in controls
(p < 0.001). Sixteen of 38 DM1 patients (39.5 %) met the criterion for apathy, contrasting with only 4 of the 19 (21.1 %)
FSHD patients. No control subject was apathetic. Moreover, apathy in DM1 patients was negatively correlated to MMSE
(r = −.46, p < .05) and Stroop Word (r = −.55, p < .01) scores, but not with age, educational level, disease duration, CTG
repeats, motor functional disability, fatigue, depression, and anxiety.
Conclusions: Apathy is a frequent symptom in DM1 (almost 40 %). It is more prevalent than in a similarly disabled group
of patients with FSHD and in controls. Results also show that apathy in DM1 is independent of the psychopathological
domain, fatigue, age, and motor disability, but associated to general cognitive status. These results altogether
could suggest a central cause for apathy in DM1 rather than an adjustment process to cope with the progressive and
debilitating nature of the disease. Data emphasize the importance to evaluate this symptom in routine clinical
management of DM1 patients.
Background
Myotonic dystrophy type 1 (DM1) is a multisystemic,
hereditary disease affecting the muscular, central ner-
vous, ocular, respiratory, cardiovascular, digestive, endo-
crine and reproductive systems [1, 2]. It is caused by an
unstable base triplet (CTG)n repeat located in the 3′ un-
translated region of the dystrophia myotonica protein
kinase (DMPK) gene on chromosome 19 [3]. DM1 is
divided into four different phenotypes according to age
at onset of symptoms: congenital; childhood; classical or
adult form; and late onset form [4].
The degree of cognitive impairment varies with the
phenotype, ranging from mental retardation and learn-
ing difficulties in the congenital [1] and childhood phe-
notypes [5] to neuropsychological impairments affecting
the higher cognitive functions in the classical adult
phenotype. More particularly, concentration and attention
problems, deficits in visuo-spatial and visuo-constructive
skills, and a tendency to rigidity and perseveration [6, 7]
were noted in patients with this latter phenotype.
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Studies have revealed that personality traits of patients
with adult onset phenotypes were characterized by perva-
sive social inhibition and avoidance of social interaction [8].
For example, low scores on the self-directedness and co-
operativeness subscales of the Temperament and Character
Inventory (TCI) were reported, respectively reflecting feel-
ings of ineptitude when faced with obstacles and difficulties
in accomplishing goals and a tendency to prefer solitude to
company and poor functioning in social groups [9].
Also, Rohrer was the first to note apathy and a lack
of motivation in patients with DM1 [10], although
Curschmann (cited in Thomasen [11]) had previously
evoked dullness as a characteristic component of the
condition. Thomasen later identified fatigue and ady-
namia as prominent symptoms of DM1 patients and
pointed out the difficulty to distinguish between true
fatigue and lack of initiative characteristic of mental
change [11]. Bungener et al. further underlined a signifi-
cant emotional deficit in this patient population, mani-
fested by a lack of expressiveness, a monotonous mood,
an inability to anticipate pleasure, and apathy, without
major depressive episode [12]. In their landmark study on
36 DM1 and 13 Charcot-Marie-Tooth (CMT) patients,
Rubinsztein and colleagues [13] specified that apathy was
more severe in patients affected by DM1 than in those af-
fected by CMT disease. Unfortunately, the authors did not
report the prevalence of apathy per se. In addition, they
found that apathy did not vary with duration of illness,
muscular weakness, depression, daytime sleepiness, and
fatigue. The absence of relationship between apathy
and depression was also noted in a subsequent smaller
study (n = 10 DM1 patients) looking at an anthiarrhytmic
drug [14]. No study has though explored the relationship
of apathy to cognitive abilities in DM1 patients.
This study aims to determine the prevalence of apathy
in DM1 patients and to compare it with that found in
patients affected by facio-scapulo-humeral dystrophy
(FSHD) and controls. FSHD has been chosen as a com-
parative group because it shares many features with the
classic adult phenotype of DM1, including autosomal
dominant inheritance, age of onset, rate of disease pro-
gression, and broad correlation between the mutation
repetitions and disease severity. On the other hand,
FSHD patients do not generally exhibit cognitive dys-
function, except in patients with very small size of the
deleted fragment [15]. A secondary objective of this
study is to explore the relationship of apathy to psycho-
pathological features, cognitive functions, fatigue, and
functional motor disability in DM1.
Methods
Participants
Patients with both DM1 and FSHD were recruited
consecutively from the National Reference Center for
diagnosis and follow-up of neuromuscular disorders
at the Pitié-Salpêtrière Hospital (Paris, France). During
an 18-month period, 39 DM1 and 22 FSHD inpatients
were invited to participate in the study. One DM1 and 3
FSHD patients refused to participate. Inclusion criteria
were: 1) age 18–70, 2) no history of major psychiatric or
other somatic illness, acquired brain injury or alcohol or
drug abuse, and 3) a molecular confirmation of the DM1
or FSHD diagnosis. Patients with congenital or childhood
DM1 phenotypes were excluded [16]. A total of 38 pa-
tients with adult or late-onset phenotypes of DM1 (22
women and 16 men; mean age (SD), 36.8 (10.2); age range,
21–60 years) and 19 FSHD (10 women and 9 men; mean
age (SD), 46.0 (13.5); age range, 20–66 years) completed
the study. Controls included 20 healthy volunteers (16
women and 4 men; mean age (SD), 38.6 (17.8); age range,
18–70). DM1 patients and control subjects were matched
by age and educational level. Since socioeconomic and
educational levels can be considered as important features
in DM1, we precisely defined the working classes of the
DM1 patients, and then, matched 2 or 1 DM1 subjects
with 1 control with the same working class and approxi-
matively the same age.
Written informed consent was obtained from all par-
ticipants after the research project was fully explained.
In accordance with the policy in the context of an
academic research with minimal risks for participants
at the time of the study, the Ethics Committee of the
University of Paris-Vincennes approved the study de-
sign and procedures.
Instruments
The 1-h research protocol was administered by a trained
psychologist.
Demographic data
The questionnaire included age, gender, and number of
completed years of schooling.
Functional disability assessment
Functional disability was assessed using the Walton
Functional Scale [17]. Scores range from 0 to 10, with a
higher score representing a higher degree of disability.
Apathy and psychopathological assessment
Apathy was assessed with the Lille Apathy Rating Scale
(LARS). The LARS is a 33-item semi-structured and
standardized interview tapping nine domains (i.e., every-
day productivity, interests, taking initiative, novelty seek-
ing, voluntary actions, emotional responses, concern,
social life, and self-awareness). Global LARS scores
range from −36 to +36, with higher scores correspond-
ing to greater apathy. The recommended cut-off score
for apathy is −16. The LARS has shown satisfactory
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inter-rater and test–retest reliability as well as excellent
concurrent and criterion related validity [18]. Its four
factorial sub-scores permits to assess the following dimen-
sions: intellectual curiosity (LARS-IC), emotion (LARS-E),
action initiation (LARS-AI), and self-awareness (LARS-
SA). Theoretically, LARS-IC, LARS-E and LARS-AI relate
to the cognitive, emotional, and behavioural goal-directed
dimensions of apathy.
The Mini International Neuropsychiatric Interview was
used to diagnose current major depressive episodes (MDE)
[19]. Severity of depressive symptoms was assessed using
the Montgomery and Asberg Depression Rating Scale
(MADRS) [20]. Scores ≥ 15 are indicative of depression.
The State-Trait Anxiety Inventory (STAI) for Adults
was used to evaluate both temporary condition of
“state anxiety” and the more general and long-standing
quality of “trait anxiety” [21]. Raw scores are transformed
in “T-Scores” corresponding to the equivalent normative
score, depending on type of anxiety (state or trait) and
gender of subject (female and male). T-scores over 55 and
65 are considered as high and very high levels of anxiety.
Cognitive assessment
All subjects underwent a formal neuropsychological test-
ing battery. The Mini Mental State Evaluation (MMSE)
was used to estimate the severity of cognitive impair-
ment [22]. The Stroop Test (Color and Word Stroop
test, [23]) was used to evaluate processing speed, atten-
tional control, and response inhibition [24]. It consists of
3 subtests, namely word reading, color naming, and color-
word interference. The Trail Making Test A and B (TMT)
was used to evaluate cognitive flexibility [25]. Finally, the
Frontal Assessment Battery (FAB) was used to evaluate
executive abilities, namely conceptualization, mental flexi-
bility, programming, sensitivity to interference, inhibitory
control, and environmental autonomy [26].
Fatigue assessment
Fatigue was assessed with the Krupp’s Fatigue Severity
Scale (KFSS) which consists of 9 questions on a 7-point
Likert scale [27]. Scores of ≥4 are indicative of fatigue.
Statistical analyses
Inter-group comparisons were performed using non-
parametric Kruskal-Wallis tests to compare the scores in
the different tests and questionnaires between the three
groups, and Mann–Whitney U Tests for post-hoc ana-
lyses. Additionally, a Pearson’s chi-square test was per-
formed to determine whether there was a significant
difference between the frequencies of apathetic subjects
in the different groups. Intra-group comparisons were
carried out with the Wilcoxon Signed rank and Fried-
man tests. Also, Spearman’s correlations were used to
assess the relationship between apathy and its possible
related factors. The significance level was set at 0.05.
SPSS 18.0 was used for statistical analyses.
Results
Socio-demographic data of DM1 and FSHD patients and
controls are shown in Table 1. FSHD patients were older
than DM1 patients (p = 0.004).
Apathy
The global score of apathy was higher in DM1 patients
than in FSHD patients (p < 0.006) and controls (p = 0.000)
(Table 2). Also, FSHD patients did not differ from controls
regarding apathy global score. In addition, 16 out of 38
DM1 patients (39.5 %) met the criterion for apathy. In
comparison, only 4 out of 19 FSHD (21.1 %) patients met
the criterion for apathy. A Pearson’s chi-square test indi-
cates that this difference observed in the proportions of
apathetic subjects did not reach the level of significance
(p = .164). No control subject was apathetic.
A difference between DM1 and FSHD patients was
noted in the “Intellectual Curiosity” (p = 0.002) domain.
In addition, differences were noted between DM1 and
controls in the “Intellectual Curiosity” (p = 0.0000),
“Emotion” (p = 0.020), “Action initiation” (p = 0.030), and
“Self-awareness” (p = 0.044) domains. No difference was
found between FSHD and control subjects relatively to
LARS sub-scores (Table 2).
Psychopathology
Nine DM1 (23.7 %) and 1 FSHD (5.3 %) patients met
the criteria of current MDE (MINI). No control sub-
ject was clinically depressed. No between group differ-
ences was observed as regards severity of depressive
symptoms (MADRS).
Mean state anxiety scores of DM1 subjects (Table 2)
are indicative of moderate anxiety while those of FSHD
Table 1 Demographic and clinical characteristics of DM1, FSHD
and control subjects
Characteristics DM1 FSHD Controls
N 38 19 20
Socio-demographic
Age in years, mean (SD) 36.0 (10.2)a 46.0 (13.5) 38.6 (17.8)
Range in years 21–60 20–66 18–70
Educational level in years,
mean (SD)
10.8 (3.6) 11.7 (4.7) 10.9 (3.1)
Clinical
CTG repeats, mean (SD) 568 (341) ─ ─
KpnI repeats, mean (SD) ─ 6.17 ─
Disease duration, mean (SD) 16.0 (8.8) 22.4 (12.5) ─
Walton Functional Scale (SD) 2.13 (1.6) 3.16 (2.1) ─
aSignificant difference between DM1 and FSHD, p < 0.05
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patients and controls are indicative of mild anxiety.
Mean trait anxiety scores of all groups are indicative
of moderate anxiety. Moreover, no between group dif-
ferences was observed in severity of state and trait
anxiety (Table 2).
Neuropsychological features
A difference between DM1 and FSHD patients was
observed for MMSE (p = 0.028), Stroop Color-Word
(p = 0.001), Stroop Interference (p = 0.011), TMT-A
(p = 0.000), and TMT-B scores (p = 0.004). Also, DM1
and controls differed as regards MMSE (p = 0.001),
FAB (p = 0.015), Stroop Color-Word (p = 0.000), Stroop
Interference (p = 0.003), TMT-A (p = 0.000), and TMT-B
scores (p = 0.003) (Table 2).
Fatigue
DM1 and FSHD patients reported higher levels of fa-
tigue than control (respectively p = 0.004 and p = 0.003)
(Table 2).
Relationships between apathy and clinical,
psychopathological, and cognitive features in DM1
No correlation was found between apathy and age, edu-
cational level, disease duration, CTG repeats, and motor
functional disability (Table 3). A Mann–Whitney U test
revealed no difference in the apathy levels of male and
female DM1 patients.
Moreover, apathy was not correlated with fatigue, de-
pression and state or trait anxiety. Additionally, no corela-
tion was found between apathy and level of depression in
the 9 subjects with a current MDE (see Additional file 1:
Table S1). Contrastively, apathy levels were negatively
correlated to MMSE (r = −.46, p = 0.019) and Stroop Word
(r = −.55, p = 0.005) scores.
Discussion
In the general population, apathy is often defined as an ab-
sence or lack of feeling, emotion, interest or concern.
Marin [28] has stressed that the lack of motivation inherent
to apathy is clinically expressed as reduced goal-directed
behavior, cognition, and emotion. He further proposed that
Table 2 Psychopathological and neuropsychological results of DM1, FSHD and control subjects
Characteristics DM1 FSHD Controls
N 38 19 20
Psychopathology
Apathy, % 39.5 21.1 0
LARS, mean (SD) −16.9 (8,5)ba −22.8 (6.3) −25.4 (4.8)
LARS-IC, mean (SD) −1.53 (1.2)ba −2.45 (.7) −2.7 (.7)
LARS-E, mean (SD) −2.1 (1.4)a −2.66 (1.2) −2.9 (1.2)
LARS-AI, mean (SD) −2.44 (1.1)a −2.73 (1.1) −3.05 (.7)
LARS-SA, mean (SD) −1.79 (2.1)a −2.3 (1.6) −2.21 (1.7)
MADRS, mean (SD) 10.3 (8.8) 7.0 (7.4) 6.1 (6.2)
STAI-A, T score, mean (SD) 50.1 (14.1) 44.8 (11) 45.3 (9)
STAI-B, T score, mean (SD) 53.3 (12.6) 48.7 (12.9) 47.1 (10.9)
KFSS, mean (SD) 4.6 (1.5)a 4.8 (1.5)c 3.3 (1.0)
Neuropsychology
MMSE, mean (SD) 27.5 (2.2)ba 28.9 (0.9) 29.3 (0.9)
FAB, mean (SD) 15.5 (1.7)a 15.9 (1.4) 16.5 (0.95)
Stroop word T score, mean (SD) 47.8 (6.6) 51.6 (8.9) 51.8 (7)
Stroop color T score, mean (SD) 44.24 (8.2) 46.56 (9.8) 49.75 (6.3)
Stroop color-word T score, mean (SD) 39.0 (9.9)ba 49.2 (7.9) 51.8 (4.9)
Stroop interference score, mean (SD) 44.47 (8.4)ba 49.68 (6.5) 50.65 (6.6)
TMT-A z score, mean (SD) 0.2 (0.7)ba 0.9 (0.4) 1.0 (0.5)
TMT-B z score, mean (SD) −0.4 (1.2)ba 0.4 (0.6) 0.4 (0.7)
LARS-IC LARS Intellectual curiosity, LARS-E LARS Emotion, LARS-AI LARS Action initiation, LARS-SA LARS Self-awareness, MADRS Montgomery Asberg Depression
Rating Scale, STAI-A state anxiety, STAI-B trait anxiety, KFSS Krupp fatigue severity scale, MMSE Mini Mental State Evaluation, FAB Frontal Assessment Battery, TMT Trail
Making Test
aSignificant difference between DM1 and Controls, p < 0.05
bSignificant difference between DM1 and FSHD, p < 0.05
cSignificant difference between FSHD and Controls, p < 0.05
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such features are not attributable to diminished level of
consciousness, cognitive impairment or emotional distress.
Apathy in DM1 has long been acknowledged in clin-
ical practice. However, a major drawback is that the con-
cept has been only sparsely explored in previous specific
studies [29]. This study demonstrates that apathy is
highly prevalent in DM1 patients compared to matched
healthy controls. Apathy is also more frequent in DM1
than in a similarly disabled group of patients with FSHD,
despite a statistical non-significance in proportions, sug-
gesting that this symptom is not only consecutive to
some adjustment process to cope with a chronic pro-
gressive neuromuscular disorder [13].
Findings also confirm the absence of relationship be-
tween apathy and age, gender, disease duration, CTG
repeats, functional impairment, and fatigue in DM1
patients [13, 14]. The absence of a significant correl-
ation between apathy and fatigue must be pointed out
considering the conceptual proximity of lack of mo-
tivation and experienced fatigue [30].
Which aetiology for apathy in DM1?
The emotional hypothesis
Apathy can easily be confounded with depression, over-
lapping with diminished interest, and loss of energy, but it
would be simplistic to reduce apathy to depression. In the
present study, no correlation was found between apathy
and depression, as reported elsewhere [13, 14]. Studies in
other neurological diseases have also concluded that ap-
athy is a separate entity from depression [18, 31, 32]. Levy
and Dubois have stated that: “… apathy is a symptom that
can be observed in depression but may also occur without
depression and, when both are present in a given patient,
they may be clinically and anatomically independent” [33].
In the present study, 10 DM1 patients were apathetic
but not depressed while 4 were only depressed.
Table 3 Correlation between apathy and sociodemographic, clinical, psychopathological and neuropsychological variables in DM1
patients
LARS-Total Score LARS-IC LARS-E LARS-AI LARS-SA
Age .130 .116 .188 −.183 .152
CTG −.024 .137 −.188 −.198 .114
DiseaseDuration .049 .076 .069 −.335* .092
Educational level −.135 −.288 .157 −.197 .023
Walton .166 .088 .095 −.127 .234
MADRS .005 .161 −.094 −.093 −.327*
StaiA .013 .214 −.045 −.221 −.451**
StaiB .056 .265 −.145 −.102 −.367*
MMSE −.464* −.457** −.042 −.032 −.130
FAB-TotalScore −.006 −.090 .135 −.031 .080
FAB-Similarities .128 .258 −.013 −.123 −.042
FAB-Lex.Fluency −.088 −.297 .018 −.001 .316
FAB-Prehension −.278 −.305 .003 −.364* .027
FAB-MotorSeries −.097 −.167 −.077 .037 .020
FAB-Conflict .028 −.045 .162 .023 −.119
FAB-GoNogo −.125 −.167 −.156 .111 −.239
StroopWord −.548** −.253 −.372* −.221 −.092
StroopColor −.091 −.060 −.093 −.204 −.060
StroopColorWord −.097 −.057 −.138 .038 −.145
StroopInterfer .060 −.016 −.009 .212 .021
TMTA −.166 −.044 −.067 .003 −.014
TMTB −.226 −.172 −.279 .039 −.252
KFSS .068 .095 −.187 .025 −.108
Spearman’s correlation
LARS.IC LARS Intellectual curiosity, LARS-E LARS Emotion, LARS-AI LARS Action initiation, LARS-SA LARS Self-awareness, MADRS Montgomery Asberg Depression
Rating Scale, MMSE Mini Mental State Evaluation; FAB Frontal Assessment Battery, TMT Trail Making Test, KFSS Krupp fatigue severity scale
**p < 0.01
*p < 0.05
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Levy et al. [31] further suggested that the diagnosis of
depression should be supported by symptoms of sadness
and feelings of helplessness, hopelessness, and worth-
lessness that should not be present in patients who are
only apathetic.
In view of the present results, one may advise clini-
cians to systematically evaluate both these symptoms
since treatment options may differ. Before classical cog-
nitive and behavioural therapy of depression is under-
taken, clinicians should also know whether a patient is
apathetic or not as self-participation into the protocol is
highly recommended to reach successful outcomes.
There are still unresolved differences of opinions as to
whether depression in DM1 is a direct result of brain dys-
function or a secondary reaction to the physical disability
or a combination of both [34]. Some authors have ad-
vanced that the relatively high prevalence of depression of
mild to moderate intensity observed in DM1 [34] is partly
attributable to symptoms of apathy, such as lack of motiv-
ation, blunted emotional concerns and reactions [12, 14].
Our results are in agreement with this position. Indeed,
even though 1 of 4 DM1 patients is clinically depressed,
their level of depression does not significantly differ from
FSHD patients and controls. Thus, there is a distinct pos-
sibility that the profile of monotonous affect and lack of
emotional expressiveness repeatedly described in DM1 is
more likely explained by apathy than pure depression.
Moreover, the lack of facial expression due to weakness of
facial muscles characteristic of DM1 may mimic depres-
sive symptoms such as emotional expressiveness, sadness
or anhedonia, leading to possible biases in diagnosis of
major depressive episodes in DM1 [34]. Finally, an overlap
between the “somatic dimension” of depression and clas-
sical symptoms of DM1 such as fatigue, sleep distur-
bances, or even reduced appetite has been described and
may explain high frequency of depression diagnoses [34].
The “central” hypothesis
Results revealed that apathy was associated with the gen-
eral cognitive status and word reading abilities, supporting
the view that apathy reflects a central nervous system in-
volvement [13] in DM1 patients. This is consistent with
previous findings in patients with other neurological con-
ditions in whom lower global intellectual status was asso-
ciated with higher levels of apathy [31, 32, 35]. Further
studies may evaluate the correlation of apathy with
more extended intelligence tests battery in DM1 (e.g.,
the Wechsler Adult Intelligence Scale). Moreover, ap-
athy is related to a dysfunction of frontal-subcortical cir-
cuits, following direct lesion of the prefrontal cortex or
after lesions of basal ganglia structures [33]. More particu-
larly, Varanese et al. found a positive relationship between
apathy and executive dysfunction levels [36].
Results yet revealed weak relationships between levels
of apathy and scores on executive function tests (coeffi-
cients varying between −0.006 and − .278). Previous
studies in other neurological diseases have shown that
apathy was associated with poor planning and rule-
finding [36] as well as high numbers of rule breaks [37],
with tasks requiring great levels of executive functioning.
It should though be underlined that these latter aspects
of executive functioning cannot be assessed with fast
and easy-to-use tests such as the ones used in the
present study. Other studies must verify whether brain
microstructural changes in fronto-subcortical circuits
are associated with apathy in DM1 patients, as it was
demonstrated in other neurological diseases [38].
Clinical relevance of apathy dimensions
This study further specifies that dimensions of apathy dif-
fer between DM1 patients and controls, in agreement with
previous observations in DM1. The emotional deficit
manifested by a lack of expressiveness and monotonous
mood [12] may be due to emotional apathy (LARS-E),
characterised by a blunting of emotional responses and
lack of concern [18]; lower social participation, namely
difficulties in carrying out daily activities and social
roles [39] may be partly attributed to the apathy’s be-
havioural (LARS-AI) [35] and cognitive dimensions
(LARS-IC & LARS-SA), reflecting respectively lack of
initiative and low everyday productivity and low inter-
est in novelty as well as drop in the perceived need
for knowledge [18]; finally, high scores in all four di-
mensions of apathy could explain, at least partly, the
lack of compliance/observance in care frequently ob-
served in DM1 patients [40].
Study limitations
Since the recruitment of subject was consecutive, the se-
lection bias should be small, as it was based on the inter-
disciplinary annual evaluation and not on the basis of a
dependent variable-specificity (i.e., patients reporting ap-
athy or cognitive complaints). Additionally, because of
the relatively small sample size and the numerous vari-
ables entered into the statistical model, results have to
be interpreted with caution. Limitations include the fact
that the LARS is a patient-based tool for which individ-
uals are required to use their own standards to evaluate
their apathy and is thus subjective to response bias.
Nevertheless, since LARS is a structured interview, clini-
cians can adjust their rating regarding their own percep-
tion of the verbal and non-verbal patients’ inputs. Future
studies may add the LARS caregiver-based version [41],
which was not yet published when this study was per-
formed. Furthermore, FSHD patients were older than
DM1. Because of the rareness of the disease, this factor
has not been controlled. Since apathy may occur in
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dementia, a link between age and apathy may be sup-
posed. Yet, age was not correlated to apathy in our re-
sults. Thus, the fact that DM1 patients were more
apathetic than FSHD patients enhances the lack of rela-
tion between age and apathy.
Also, the neuropsychological battery used here does
not consider the demands of the real world in regards to
daily life barriers encountered by DM1 patients, such as
“multitasking” situations for which apathy is likely to ap-
pear preferentially [37]. Further studies combining
neuropsychological and psychopathological features of
DM1 patients and their implications into psycho-social
interactions are thus needed. Moreover, studies should
use measurement instruments that are sensitive to the
level of accomplishment of instrumental activities of
daily living [42], in terms of both executive processes
and motivational aspects involved in goal-directed be-
havioural, cognitive and emotional activities (e.g., the
Gambling task [43] or the multiple errands shopping test
[44]). Finally, further studies on apathy in DM1 should
also aim at describing its progression and test experi-
mental treatments.
Conclusions
This is the first study of prevalence to show that apathy
is more frequent in DM1 than in healthy normal sub-
jects and in another neuromuscular disorder, namely the
FSHD. Among the apathetic DM1 patients, the severity
of their symptoms may constitute an additional barrier
to patients’ social involvement. Since apathy has been
described as the main source of complaint and psycho-
logical distress in neurologic patients’ family or care-
givers [45], a better comprehension of apathy and its
outcomes in DM1 is relevant. In this regard, a clinical
routine evaluation of apathy in DM1 is advised.
In addition, results imply that apathy is independent of
the psychopathological domain, fatigue, sleepiness, age,
gender and motor disability, contrasting with its negative
relationships with some of the neuropsychological indi-
ces. These results altogether could suggest a central
cause for apathy in DM1 rather than an adjustment
process to cope with the progressive and debilitating na-
ture of the disease.
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